ArticleBMC veterinary research2025
An extensively hydrolysed protein-based extruded diet in the treatment of dogs with chronic enteropathy and at least one previous diet-trial failure: a pilot uncontrolled open-label study.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and Faecal Outcomes in Adult Dogs with Chronic Enteropathy Fed an Hydrolysed Protein Diet with and WithoutAnimals : an open access journal from MDPI · 2026Article
- Rethinking clinical response criteria in trials of chronic enteropathy in dogs: what change is truly meaningful?Journal of veterinary internal medicine · 2026Article
- The alleviating effects and mechanisms ofFrontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCanine chronic enteropathies (CE) are a group of disorders defined by persistent or recurrent clinical signs of gastrointestinal disease without a primary neoplastic, metabolic, parasitic, or other infectious cause. In this prospective, multicentre, uncontrolled, open-label study, a commercial dry diet with a protein source of extensively hydrolysed poultry feather was assessed in the management of dogs with CE that had not responded to previous dietary and antibacterial therapies. Dogs with moderate or marked protein-losing enteropathy were excluded. After screening, dogs entered stage 1 and started the test diet. Gastrointestinal endoscopy was performed, and only dogs with histopathological evidence of small intestinal inflammation confirming CE could continue to stage 2 of the trial. The test diet was fed for 10 weeks throughout stages 1 and 2, and the primary outcome measure was clinical success defined as a reduction in canine inflammatory bowel disease activity index (CIBDAI) of ≥ 75%. Secondary outcomes included body condition score (BCS, scale 1-9) and faecal consistency score (scale 1-5). Results (median [range]) for dogs with confirmed CE that participated in both study stages are reported.
resultsA total of 15 dogs commenced stage 1, and 13 of these progressed to stage 2 (age 4.2 [1.1-7.1] years; BCS 3 (2-4); previous diet therapies 2 [1-3]) of which two were withdrawn at week 5 for protocol deviations. CIBDAI scores decreased from 9 (7-16; n = 13) at baseline to 2 (1-11; n = 13) at week 2 (P < 0.001), 2 (0-6; n = 13) at week 5 (P < 0.001), and 1 (0-3; n = 11) at week 10 (P < 0.001). Treatment success was achieved by 8/13 dogs at week 5 and 10/11 dogs at week 10. Faecal score (n = 11) and BCS (n = 11) improved between baseline (1 [1-3] and 3 [3-4], respectively; P < 0.001) and week 10 (4 [3-5] and 4 [3-5], respectively; P < 0.001).
conclusionsDogs with CE that had failed to respond to previous dietary and antibacterial therapy showed clinical improvement within 10 weeks when fed a dry extruded diet with a single protein source hydrolysed to amino acids and oligopeptides, without concurrent immunosuppressant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.